Syndax Pharmaceuticals, Inc


Syndax Pharmaceuticals is dedicated to developing innovative therapies for cancer patients, focusing on areas such as acute leukemias, chronic graft-versus-host disease, and other focus areas. They aim to improve patient outcomes through their pipeline of clinical studies and products.

Industries

biotechnology
clinical-trials
health-care
pharmaceutical

Nr. of Employees

medium (51-250)

Syndax Pharmaceuticals, Inc

Waltham, Massachusetts, United States, North America


Products

Therapeutic candidates for hematologic malignancies

Investigational therapeutic agents in development targeting blood cancers and related disorders; portfolio includes multiple clinical-stage candidates.


Services

Clinical study conduct

Execution and management of multicenter clinical trials for investigational therapeutics in oncology.

Compassionate use / expanded access

Provision and administration of expanded access programs to supply investigational therapies outside of formal trials.

Patient resources and enrollment support

Patient-directed information and contact resources to support trial enrollment and program inquiries.

Expertise Areas

  • Clinical trial management
  • Expanded access / compassionate use programs
  • Oncology drug development
  • Hematologic malignancies (acute myeloid leukemia, KMT2A-rearranged, NPM1-mutant; chronic graft-versus-host disease)
  • Show More (3)

Key Technologies

  • Clinical trial implementation
  • Expanded access program administration
  • Oncology therapeutic development
  • Preclinical-to-clinical pipeline management
  • Show More (1)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.